Magnitude Biosciences

Investor: Northstar Ventures

Magnitude Biosciences has secured £1.3 million in funding to expand its VivoScan screening platform and accelerate drug discovery operations.Summary of transaction details:Value: £1.3 millionSector: Healthcare & BiotechAdvisor: Not disclosedKey Entities: Magnitude Biosciences, Northstar VenturesLocation: Sedgefield, County DurhamNote: The investment will enable the biosciences firm to scale its proprietary technology targeting ageing and neurodegenerative diseases, supporting international expansion and job creation.

Investor: Northstar Ventures

Magnitude Biosciences, a Durham University spinout specializing in whole-organism drug discovery, has successfully raised £1.3 million in funding to scale its technology and expand commercial operations.Summary of transaction details:Value: £1.3 millionSector: Healthcare & BiotechAdvisor: Not disclosedKey Entities: Magnitude Biosciences, Northstar Ventures, Maven Equity Finance, Finance Durham FundLocation: Durham, United KingdomNote: The investment aims to accelerate the deployment of the company's VivoScan platform, addressing the pharmaceutical industry's growing need for faster, cost-effective alternatives to traditional mammalian testing in areas such as ageing and neurodegenerative diseases.